Please see the full-text version of this guideline (https://www.cns.org/guidelines/guidelines -management-patients-vestibular-schwannoma/chapter_3) for the target population of each recommendation listed below. STEREOTACTIC RADIOSURGERY Question 1: What is the overall probability of maintaining serviceable hearing following stereotactic radiosurgery utilizing modern dose planning, at 2, 5, and 10 yr following treatment? Recommendation: Level 3: Individuals who meet these criteria and are considering stereotactic radiosurgery should be counseled that there is moderately high probability (>50%-75%) of hearing preservation at 2 yr, moderately high probability (>50%-75%) of hearing preservation at 5 yr, and moderately low probability (>25%-50%) of hearing preservation at 10 yr. Question 2: Among patients with AAO-HNS (American Academy of OtolaryngologyHead and Neck Surgery hearing classification) class A or GR (Gardner-Robertson hearing classification) grade I hearing at baseline, what is the overall probability of maintaining serviceable hearing following stereotactic radiosurgery, utilizing modern dose planning, at 2, 5, and 10 yr following treatment? Recommendation: Level 3: Individuals who meet these criteria and are considering stereotactic radiosurgery should be counseled that there is a high probability (>75%-100%) of hearing preservation at 2 yr, moderately high probability (>50%-75%) of hearing preservation at 5 yr, and moderately low probability (>25%-50%) of hearing preservation at 10 yr. Question 3: What patient-and tumor-related factors influence progression to nonserviceable hearing following stereotactic radiosurgery using ≤13 Gy to the tumor margin? Recommendation: Level 3: Individuals who meet these criteria and are considering stereotactic radiosurgery should be counseled regarding the probability of successful hearing preservation based on the following prognostic data: the most consistent prognostic features associated with maintenance of serviceable hearing are good preoperative word recognition and/or pure tone thresholds with variable cut-points reported, smaller tumor size, marginal tumor dose ≤12 Gy, and cochlear dose ≤4 Gy. Age and sex are not strong predictors of hearing preservation outcome.
O
ver the last 100 years, there has been a significant shift in vestibular schwannoma (VS) outcome priorities. 1, 2 The evolution in treatment over the last century has ultimately led to an environment where functional outcome has taken precedence over disease eradication. 3 Fueled by disparate study methodology and heterogeneous reporting, a general consensus regarding long-term preservation of useful hearing is lacking. [4] [5] [6] 
METHODS
Details of the systematic literature review are provided in the full text of this guideline (https://www.cns.org/guidelines/guidelinesmanagement-patients-vestibular-schwannoma/chapter_3) and in the methodology article (https://www.cns.org/guidelines/guidelines-manage ment-patients-vestibular-schwannoma/chapter_1) of this guideline series. The authors searched articles published from January 1, 1990 to December 31, 2014. Three electronic databases, PubMed, EMBASE, and Web of Science were searched ( Table 1 , https://www.cns.org/guide lines/guidelines-management-patients-vestibular-schwannoma/chapter _3/table1). The selected articles were classified according to criteria for evidence on prognosis as detailed in the Joint Guidelines Committee (JGC) Guideline Development Methodology (https://www.cns. org/guidelines/guideline-procedures-policies/guideline-developmentmethodology).
RESULTS
A total of 1307 studies were screened and assessed for eligibility, and 47 publications pertaining to stereotactic radiation were included in the final review. Class III evidence supports the conclusion that the risk of hearing loss increases with time, well beyond the first 2 yr following radiation treatment ( Table 2 , https://www.cns.org/guidelines/guidelines-management-patients -vestibular-schwannoma/chapter_3/table2). 30, 53 A total of 1307 studies were screened and assessed for eligibility, and 37 studies pertaining to microsurgery were included in the final review. 32, 36, Class III evidence supports the conclusion that the greatest risk to hearing with surgery occurs upfront. If hearing is initially preserved following surgery, the results tend to be durable (Table 3 , https://www.cns.org/guidelines/guidelinesmanagement-patients-vestibular-schwannoma/chapter_3/table3).
A total of 1307 studies were screened and assessed for eligibility, and 17 studies pertaining to observation were included in the final review. 2, 23, 30, 53, 65, [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] Class III evidence supports the conclusion that the risk of hearing loss increases with time during conservative management. The 2 strongest prognostic factors for the development of nonserviceable hearing are tumor growth and poorer hearing at the beginning of observation (Table 4 , https://www.cns.org/guidelines/guidelines-management-patients -vestibular-schwannoma/chapter_3/table4). 
ABBREVIATIONS: AAO-HNS,

DISCUSSION AND CONCLUSION
In summary, these data demonstrate that consistent and durable hearing preservation in sporadic VSs remains an elusive goal. Most patients eventually develop nonserviceable hearing as a result of disease or treatment.
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This clinical systematic review and evidence-based guideline was developed by a multidisciplinary physician volunteer task force and serves as an educational tool designed to provide an accurate review of the subject matter covered. These guidelines are disseminated with the understanding that the recommendations by the authors and consultants who have collaborated in their development are not meant to replace the individualized care and treatment advice from a patient's physician(s). If medical advice or assistance is required, the services of a competent physician should be sought. The proposals contained in these guidelines may not be suitable for use in all circumstances. The choice to implement any particular recommendation contained in these guidelines must be made by a managing physician in light of the situation in each particular patient and on the basis of existing resources.
